Envista Holdings Price Target Cut to $17.00/Share From $19.00 by Baird
Envista Holdings Is Maintained at Neutral by Baird
Baird Maintains Envista Holdings(NVST.US) With Hold Rating, Cuts Target Price to $17
Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus
Envista Holdings: Hold Rating Maintained Amidst Executive Appointments and Uncertain Impact on Financial Performance
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Evercore Maintains Envista Holdings(NVST.US) With Buy Rating, Cuts Target Price to $19
BofA Securities Maintains Envista Holdings(NVST.US) With Buy Rating, Maintains Target Price $22
A Quick Look at Today's Ratings for Envista Holdings(NVST.US), With a Forecast Between $18 to $22
Analysts' Top Healthcare Picks: Accolade (ACCD), Envista Holdings (NVST)
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Select Medical (SEM)
Expert Outlook: Envista Holdings Through The Eyes Of 5 Analysts
Express News | Needham Reiterates Hold on Envista Holdings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Envista Holdings (NVST), Johnson & Johnson (JNJ) and CVS Health (CVS)
Express News | Envista Holdings Names Eric Hammes As CFO, Effective August 8, 2024
Express News | Envista Holdings Corp: Eric Hammes Joins Envista as Chief Financial Officer
Express News | Envista Holdings Corporation Announces Key Leadership Appointments
Envista Schedules Second Quarter 2024 Earnings Call
Morgan Stanley Maintains Envista Holdings(NVST.US) With Hold Rating, Cuts Target Price to $19
Morgan Stanley Remains a Hold on Envista Holdings (NVST)
No Data